Novel 10 kHz rapifleX Offers Breakthrough TOF/TOF Performance and
Robustness for Primary Structure and PTM Determination in Proteomics,
MALDI Tissuetyping and Biopharma Applications
VANCOUVER, British Columbia--(BUSINESS WIRE)--
At the 14th Human Proteome Organization World Congress
(HUPO), Bruker today announced the new rapifleX MALDI-TOF/TOF
mass spectrometer. MALDI-TOF/TOF is established as a powerful tandem
mass spectrometry method for in-depth protein analysis. With its
redesigned, next-generation TOF/TOF ion optics, the rapifleX system
now offers significantly higher speed, mass resolution and mass accuracy.
The rapifleX integrates a novel, 10 kHz smartbeam™ 3D
scanning laser design for breakthrough mass-spec imaging capabilities
with dramatically improved spatial resolution, image contrast and
quality, and a new ion source for superior robustness and throughput in
pathology research.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20150928006154/en/
Tissue- and cell-type specific proteomics is a major advance for
relevant biomarker discovery and identification, and requires MALDI
tissue imaging studies which include the identification of detected
biomarker candidates for validation and the subsequent development of
targeted assays. The rapifleX MALDI-TOF/TOF extends the MALDI
Tissuetyper® imaging capabilities with rapid, spatially resolved
MS/MS data. It supports the patented ImageID™ workflow for
biomarker discovery in MALDI imaging cohort studies by obtaining
matching identifications of tryptic peptides in bottom-up imaging
studies.
Dr. Dietrich Hauffe, Executive Vice President for Life Science Mass
Spectrometry at Bruker Daltonics, commented: “With the rapifleX MALDI-TOF/TOF
introduction, we can now offer both, greatly enhanced TOF/TOF
performance for structural characterization, and breakthrough MS imaging
capabilities for cutting-edge proteomics research laboratories, for
biopharma customers, and for clinical researchers in pathology. Its
unparalleled speed, throughput, structural capabilities, imaging
capabilities, as well as MALDI ease of use and robustness, make the new rapifleX
MALDI-TOF/TOF a game-changing new research and validation tool.”
About the rapifleX MALDI-TOF/TOF system
In addition to next-generation tissue imaging performance, the rapifleX
MALDI-TOF/TOF system is well suited for detailed protein
characterization in life science research and biopharmaceutical
laboratories. The rapifleX MALDI-TOF/TOF system will improve many
protein characterization tasks:
-
Peptide mass fingerprints for protein identification
-
Fast identification of post-translational modifications (PTM)
-
Fast identification of impurities
-
Top-down protein sequencing
-
T3-Sequencing to identify or confirm suspected
modifications or sequence alterations at protein N- or C-termini. T3-Sequencing
is patented for protein terminal structure determination.
-
Fully automated Disulfide Bond analysis of intact proteins without a
priori assumptions using DisulfideDetect™ method and software.
The rapifleX™ MALDI-TOF/TOF system is
for research use only.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve the
quality of human life. Bruker’s high-performance instruments and
high-value analytical solutions enable scientists to explore life and
materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular research, in
applied and pharma applications, in microscopy, Nano-analysis and
industrial applications, as well as in cell biology, preclinical
imaging, clinical research, microbiology and molecular diagnostics. For
more information, please visit www.bruker.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150928006154/en/
Source: Bruker Corporation